Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5234_Библиотеки_им_академика_М_И_Перельмана
.pdf
84 Computational Intelligence Algorithms
and development by helping discover new biomarkers for neurological illnesses by
nding predictive patterns in neuroimaging data. They improve clinical trial design
and efcacy by employing predictive models to choose appropriate participants and
endpoints. Predictive modeling in neuroimaging uses ML to help improve patient
care through early diagnosis, personalized therapy, and better results. These models
give vital insights that help doctors make informed decisions, improving the efcacy
and efciency of neurological care [16].
7.2.5 ATLAS-BASED APPROACHES
AI can improve brain atlases by incorporating fresh imaging data, boosting anatomical landmark precision, and assisting with the localization of brain regions of interest. Enhanced precision of anatomical landmarks incorporates fresh imaging data
into brain atlases, enabling continual rening and enhanced accuracy and resulting
in more exact localization of brain areas, which is critical for diagnostic accuracy
and surgical planning.
Improved localization of brain areas: Rened atlases provide precise and accurate maps of brain areas, making it easier to identify small or obscure anatomical
features. They improve localization and the correlation of anatomical abnormalities
with functional deciencies, resulting in a better knowledge of neurological diseases.
Guidance in surgical and therapeutic interventions: Accurate atlases help neurosurgeons plan and execute procedures, lowering the chance of injuring crucial brain
areas. This helps to target specic brain regions for therapies like deep brain stimulation or tailored medication delivery [17].
Facilitation of research and education: Rened atlases are invaluable in neuroscientic research because they provide a consistent reference for comparing anatomical and functional data across studies. They serve as complete teaching resources for
medical students and professionals, improving their understanding of brain anatomy
and function.
7.2.6 HIGH-DIMENSIONAL DATA ANALYSIS
Tensor decomposition and manifold learning are useful techniques for handling and
interpreting the high-dimensional data generated by neuroimaging investigations,
allowing for a better understanding and visualization of complicated brain activity
patterns. These techniques improve our understanding of the brain’s structure and
function, resulting in more accurate diagnostic tools and treatments for neurological
diseases.
Enhanced data interpretation: Neuroimaging techniques generate massive
amounts of high-dimensional data, which is difcult to analyze. Tensor decomposition and manifold learning are useful techniques for simplifying and analyzing such
data, resulting in better insights into brain function and pathology.
Improved diagnostic accuracy: High-dimensional data analysis can reveal subtle
patterns and abnormalities that regular analysis approaches may miss. Advanced
pattern recognition enables the early diagnosis of neurological illnesses such as
Alzheimer’s, Parkinson’s, and epilepsy [18].
Advancements in Neuroimaging Techniques in Encephalopathy
Personalized medicine is the practice of tailoring treatment strategies to individual patients’ unique high-dimensional data proles. Such practice improves therapy efcacy by focusing on specic brain regions and functions uncovered through
enhanced data analysis. Advanced research involves identifying novel biomarkers
for a variety of neurological and mental diseases. Gaining better insights into the
dynamic interactions of the brain will help to develop neuroscience [19].
85
7.3 OPTICAL IMAGING AND BRAIN-MACHINE INTERFACES
Optogenetics is a technique that uses light to regulate neurons that have been genetically engineered to be light-sensitive. It enables precise regulation of neural activity
in animal models, revealing details about brain function and behavior.
Brain-machine interfaces (BMI) allow direct contact between the brain and
external devices, which has the potential to restore function in paralyzed people
while also enhancing our understanding of neural code.
Optical imaging techniques are generally noninvasive and repeatable, making
them excellent for longitudinal research. Real-time monitoring of brain activity
is useful for gaining insights into cerebral hemodynamics and oxygenation. Nearinfrared spectroscopy (NIRS) techniques are portable and can be employed at the
bedside, allowing for brain monitoring in critical care settings such as neonatal
intensive care units. They allow for the imaging of brain activity, which is useful in
cognitive neuroscience and studying brain function in both health and sickness [20].
BMIs can restore motor functions in paralyzed or limb-amputation patients by
allowing them to control prosthetic limbs or external devices. BMIs can help people
with severe motor disabilities communicate more effectively, improving their quality of life. They can be used in rehabilitation programs to retrain motor functions
following a stroke. BMIs can also be used in neurofeedback therapy to help patients
regulate brain activity, which may aid in the treatment of diseases such as attention
decit hyperactivity disorder (ADHD) or anxiety [21].
7.4 BENEFITS OF AI-RELATED ADVANCES IN
NEUROIMAGING TECHNIQUES
CNNs provide signicant advantages over standard neuroimaging techniques. These
benets include accuracy, efciency, and the ability to handle complex data. Here are
several signicant advantages:
1. Automatic feature extraction, the traditional approach, identies signicant
image properties mostly through handcrafted features and topic expertise. Manual feature extraction is time-consuming and subject to human
mistakes. CNNs learn and extract hierarchical features from raw image
data automatically, without the need for operator intervention. They capture intricate patterns and systems that may be invisible to human experts.
CNNs adapt to fresh data and improve performance over time. Variability
exists owing to differences in operators and subjective interpretations.
86 Computational Intelligence Algorithms
Automatic feature extraction is often less accurate at detecting subtle or
minor anomalies [21].
2. CNNs produce consistent results by eliminating human variability from the
equation. They can learn from enormous volumes of data and nd minute
patterns, allowing them to detect and classify problems with greater precision.
CNNs outperform established methods for tumor identication, segmentation,
and classication. Traditional neuroimaging struggles with high-dimensional
data, necessitating dimensionality reduction approaches that may result in the
loss of valuable information. Such neuroimaging has limited ability to handle
multimodal data (for example, combining MRI, PET, and fMRI) [7, 22].
3. CNNs are capable of processing enormous amounts of high-dimensional
data effectively. They integrate multimodal data to enable more thorough
analysis, improving diagnostic accuracy and understanding of brain illnesses. CNNs use innovative architectures and layers to efciently handle
and comprehend complicated data structures.
4. Once trained, CNNs can swiftly analyze and interpret neuroimaging data,
dramatically lowering diagnostic and analysis time. They enable real-time
processing and decision-making, which is vital in healthcare applications
where prompt intervention is required [9, 23].
7.5 EARLY DIAGNOSIS AND PROGNOSIS
Traditional neuroimaging may miss early symptoms of disorders that are difcult
to identify using the human eye or traditional algorithms. Diagnosis is frequently
based on obvious symptoms or severe disease stages. Such neuroimaging detects
subtle changes and early indicators of neurological disorders, allowing for earlier
diagnosis and treatment. Analyzing patterns and trends in imaging data over time
can help predict disease progression and patient prognosis [5]. Performance varies
substantially depending on the dataset and imaging settings. Traditional neuroimaging is frequently adapted to individual objectives, with insufcient generalization
across varied applications. CNNs are good at generalizing across varied datasets and
imaging circumstances because of their capacity to learn from diverse data sources.
They provide reliable performance in a variety of neuroimaging tasks, including
segmentation, classication, and detection [8, 24].
Traditional neuroimaging has had limited integration with new technologies like
augmented reality (AR) and virtual reality (VR). CNNs are easily integrated with
other cutting-edge technologies, improving visualization and interaction with neuroimaging data. They support sophisticated applications like surgical planning and
navigation with AR and VR.
7.6 LIMITATIONS OF ADVANCED
NEUROIMAGING TECHNIQUES
Advanced neuroimaging techniques, such as MRI and PET scans, have several
restrictions, including cost and accessibility, technological constraints, invasiveness and safety concerns, interpretation difculties, physiological limitations, and
87Advancements in Neuroimaging Techniques in Encephalopathy
ethical and privacy problems. These constraints can limit access for individuals and healthcare systems, particularly in low-income areas. Techniques such as
fMRI and electroencephalogram (EEG) provide excellent spatial resolution but
low temporal precision, whereas CT and PET require ionizing radiation. These
limitations underline the importance of continued improvements and cautious
consideration when using advanced neuroimaging techniques in both research
and therapeutic contexts.
7.7 CONCLUSIONS
AI-based neuroimaging techniques, particularly those that use advanced models
such as CNNs and GANs, provide dramatic advantages over traditional methods. These gains extend to data processing, analytical accuracy, and therapeutic
applications, signicantly improving the area of neuroimaging. AI approaches,
like CNNs, automate the feature extraction process, minimizing the need for
manual involvement and lowering the likelihood of human error. This automation
improves accuracy in detecting and classifying neurological diseases, allowing
for earlier and more reliable diagnoses than older techniques. GANs and other AI
models can produce synthetic data to supplement existing datasets and overcome
data scarcity constraints. This capacity guarantees more complete training datasets, resulting in the creation of more robust and generalizable models. As a result,
AI-driven systems provide consistent performance across a wide range of datasets and imaging settings, outperforming traditional neuroimaging techniques. AI
approaches, such as super-resolution GANs, improve the resolution and quality of
neuroimaging data. This enhancement allows for the discovery of small anomalies and improved visualization of brain regions, resulting in more accurate and
detailed studies that conventional approaches may struggle to achieve. AI-driven
neuroimaging processes are far faster than traditional methods, allowing for realtime analysis and decision-making. This speed is signicant in clinical applications that require prompt diagnosis and action, such as acute stroke detection
and emergency treatment. The ability of AI models to generate high-quality synthetic data minimizes the need for large and costly neuroimaging experiments.
This reduction in data-collecting costs makes advanced neuroimaging techniques
more accessible, allowing for wider use in both research and clinical settings.
AI approaches standardize data processing and analysis, which reduces variability caused by diverse imaging processes and equipment. This standardization
improves the reliability and repeatability of neuroimaging studies, resulting in
overall higher-quality research ndings and clinical outcomes. Advanced applications enabled by AI approaches include early identication of Alzheimer’s disease, precise localization of epileptic foci, and automated segmentation of brain
tumors and MS lesions. These skills help with personalized treatment regimens,
surgical outcomes, and patient management.
In conclusion, AI-based neuroimaging techniques outperform traditional
methods in terms of accuracy, efciency, and versatility. AI-driven techniques
are transforming the eld of neuroimaging by leveraging automated feature
extraction, synthetic data production, higher picture resolution, and consistent
88 Computational Intelligence Algorithms
performance, resulting in better diagnostic tools, more effective treatments, and,
ultimately, better patient care. The use of AI in neuroimaging is a paradigm
change that offers the promise of propelling neurological research and clinical
practice to new heights.
REFERENCES
1. Kandel, E. R., Schwartz, J. H., Jessell, T. M., Siegelbaum, S. A., & Hudspeth, A. J.
(2013). Principles of Neural Science (5th ed.). McGraw-Hill Education.
2. Bear, M. F., Connors, B. W., & Paradiso, M. A. (2020). Neuroscience: Exploring the
Brain (4th ed.). Wolters Kluwer.
3. Purves, D., Augustine, G. J., Fitzpatrick, D., Hall, W. C., LaMantia, A.-S., Mooney, R.
D., Platt, M. L., & White, L. E. (2018). Neuroscience (6th ed.). Oxford University Press.
4. Raichle, M. E. (2009). A brief history of huma n brain mapping. Trends in Neurosciences,
32(2), 118–126.
5. Frackowiak, R. S. J., Ashburner, J., Penny, W. D., & Zeki, S. (2004). Human Brain
Function (2nd ed.). Academic Press.
6. Roy, S., et al. (2018). Multiple Sclerosis Lesion Segmentation from Brain MRI via Fully
Convolutional Neural Networks. Scientic Reports.
7. Li, X., Morgan, V. L., Ashwath, R. C., & Conrad, B. N. (2020). Deep learning-based
detection of epileptogenic zones in MRI-negative focal cortical dysplasia. IEEE
Journal of Biomedical and Health Informatics, 24(2), 474–481.
8. Kamnitsas, K., et al. (2017). Kamnitsas, K., Ledig, C., Newcombe, V. F. J., Simpson, J.
P., Kane, A. D., Menon, D. K., Rueckert, D., & Glocker, B. (2017). Efcient multi-scale
3D CNN with fully connected CRF for accurate brain lesion segmentation. Medical
Image Analysis, 36, 61–78.
9. Pereira, S., Pinto, A., Alves, V., & Silva, C. A. (2016). Brain tumor segmentation using
convolutional neural networks in MRI images. IEEE Transactions on Medical Imaging,
35(5), 1240–1251.
10. Daoud, H., & Bayoumi, M. (2019). Deep learning approach for epileptic focus localization. IEEE Transactions on Biomedical Circuits and Systems, 14(2), 209–220.
11. Xue, Y., Farhat, F. G., Boukrina, O., Barrett, A. M., Binder, J. R., Roshan, U. W., &
Graves, W. W. (2020). A multi-path 2.5 dimensional convolutional neural network system for segmenting stroke lesions in brain MRI images. NeuroImage: Clinical, 25,
102118.
12. Goodfellow, I., Pouget-Abadie, J., Mirza, M., Xu, B., Warde-Farley, D., Ozair, S., &
Bengio, Y. (2020). Generative adversarial networks. Communications of the ACM,
63(11), 139 –144.
13. Ledig, C., Theis, L., Huszár, F., Caballero, J., Cunningham, A., Acosta, A., & Shi, W.
(2017). Photo-realistic single image super-resolution using a generative adversarial network. In Proceedings of the IEEE conference on computer vision and pattern recognition (pp. 4681–4690).
14. Goodfellow, I. (2016). Nips 2016 tutorial: Generative adversarial networks. arXiv pre-
print arXiv:1701.00160.13
15. Illes, J., & Racine, E. (2005). Imaging or imagining? A neuroethics challenge informed
by genetics. American Journal of Bioethics, 5(2), 5–18.
16. Power, J. D., et al. (2012). Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage, 59(3), 2142–2154.
17. Poldrack, R. A. (2006). Can cognitive processes be inferred from neuroimaging data?
Trends in Cognitive Sciences, 10(2), 59–63.
Advancements in Neuroimaging Techniques in Encephalopathy
18. Venkatraghavan, V., Voort, S. R. van der, Bos, D., Smits, M., Barkhof, F., Niessen, W.
J., Klein, S., & Bron, E. E. (2023). Computer-aided diagnosis and prediction in brain
disorders. Neuromethods, 197, 459–490. https://doi.org/10.1007/978-1-0716-3195-9_15.
19. Smith-Bindman, R., Miglioretti, D. L., & Larson, E. B. (2008). Rising use of diagnostic
medical imaging in a large integrated health system. Health Affairs, 27(6), 1491–1502.
20. Logothetis, N. K. (2008). What we can do and what we cannot do with fMRI. Nature,
453(7197), 869–878.
21. Brenner, D. J., & Hall, E. J. (2007). Computed tomography—an increasing source of
radiation exposure. New England Journal of Medicine, 357(22), 2277–2284.
22. Walther, J., Gaertner, M., Cimalla, P., Burkhardt, A., Kirsten, L., Meissner, S., &
Koch, E. (2011). Optical coherence tomography in biomedical research. Analytical and
Bioanalytical Chemistry, 400, 2721–43.
23. Min, B. K., Marzelli, M. J., & Yoo, S. S. (2010). Neuroimaging-based approaches in the
brain–computer interface. Trends in Biotechnology, 28(11), 552 –560.
24. Singh, S. P., Mishra, S., Gupta, S., Padmanabhan, P., Jia, L., Colin, T. K., Tsai, Y. T.,
Kejia, T., Sankarapillai, P., Mohan, A., & Gulyás, B. (2023). Functional mapping of the
brain for brain–computer interfacing: A review. Electronics, 12(3), 604.
89
Targeted Drug Delivery for
8
Neurological Disorders
Bhupen Kalita
8.1 INTRODUCTION TO TARGETED DRUG
DELIVERY IN NEUROLOGY
The nervous system is affected by varieties of neurological disorders ranging from
degenerative diseases to acute injuries (Table 8.1). Central nervous system (CNS) disorders contribute up to 6.3% of all diseases worldwide [1]. Alzheimer’s disease (AD) is a
progressive neurodegenerative condition characterized by cognitive decline and memory loss, rst dened by Alois Alzheimer in 1906 [2]. Genetic studies have identied
risk factors associated with familial and sporadic forms of AD, inuencing personalized
medicine approaches [3]. Research ndings designate the role of amyloid-beta and tau
proteins in the pathogenesis of AD, leading to the development of novel biomarkers for
early detection [4]. Parkinson’s disease (PD) is a movement disorder and is character-
ized by motor symptoms like tremors and bradykinesia and generally seen later in life,
attributed to the loss of dopaminergic neurons in the substantia nigra of the brain [5].
Stroke is an acute neurological disorders and leading cause of disability and mortality worldwide. Advances in antiplatelet therapy and endovascular procedures have contributed in acute stroke care [6]. Moreover, neuroimaging innovations like computed
tomography (CT) angiogram and diffusion-weighted and susceptibility-weighted magnetic resonance imaging (MRI) have upgraded stroke diagnosis and prognosis [7].
Management of autoimmune diseases like amyotrophic lateral sclerosis (ALS) and
multiple sclerosis (MS) have beneted from genome-wide association studies (GWAS)
and gene editing technologies, offering avenues for targeted therapies [8].
8.2 OVERVIEW OF CONVENTIONAL DRUG
DELIVERY METHODS
The conventional drug delivery methods in neurological disorders aimed at effectively transporting therapeutic agents across the blood−brain barrier (BBB) to reach
specic regions of the central nervous system (CNS).
8.2.1 ORAL ADMINISTRATION
Oral drug delivery for brain disorders faces challenges due to poor BBB permeability and enzymatic degradation of the drug agent in the gastrointestinal tract
(GI). Advances in formulation technologies aim to enhance drug bioavailability
[9]. For chronic illness, oral drug administration offers greatest convenience in
90
DO I: 10.1201/ 97810 03520 34 4 -10
91 Targeted Drug Delivery for Neurological Disorders
TABLE 8.1
Neurological Disorders and Their Symptoms, Pathophysiology,
and Common Risk Factors
Neurological Pathophysiological
Disorders Symptoms Mechanism Risk Factors
Alzheimer’s disease Gradual decline of Accumulation of Aging, diabetes, stroke,
memory, reasoning, abnormal neuritic heart problems,
and handling of plaques and depression, genetic
complex tasks, neurobrillary tangles history, lifestyle.
behavior, and in the brain leading to
personality. loss of neurons.
Stroke Trouble in speaking and Ischemic stroke- High blood pressure,
understanding, decient blood and heart disease,
confused, slur words; oxygen supply to the diabetes, smoking,
numbness, weakness or brain; hemorrhagic high blood lipids,
paralysis in the face, stroke-bleeding or excessive alcohol use.
arm, or leg. leaky blood vessels in
the brain.
Parkinson’s disease Tremor in hands, arms, Nerve cells in the basal Advancing age, men
legs, jaw, or head; ganglia become are more likely to
muscle stiffness, impaired leading to develop PD, genetics,
slowness of movement, decreased secretion of environmental causes,
impaired coordination. dopamine that causes brain trauma.
movement problems.
Epilepsy and Staring, jerking of the Disrupted balance Genetic factors,
seizures arms and legs, between excitatory and developmental brain
stiffening of the body, inhibitory abnormalities,
loss of consciousness, neurotransmitters at infection, traumatic
breathing problems. the synaptic level can brain injury (TBI).
result in seizure
activity.
Multiple sclerosis Numbness in one or Formation of plaques in
more limbs, tingling, CNS along with
electric-shock inammation,
sensations (Lhermitte demyelination, axonal
sign), lack of damage, and axonal
coordination, unsteady loss. It is an
gait or inability to autoimmune disease
walk, partial or caused by autoreactive
complete loss of vision, immune cells that
usually in one eye at a traverse BBB and
time. attack the CNS.
Migraine Intense throbbing or dull Imbalance in brain Family history,
aching pain in head, neurotransmitters, hormonal changes in
stiff or tender neck, including serotonin, women, adolescence
lightheadedness. calcitonin gene-related and younger age.
peptide (CGRP).
15−50 years of age,
women are at more
risk, North Europeans
are at higher risk,
those living at 40˚C
and above, family
history, certain viral
infections and
autoimmune diseases.
(Continued)
92 Computational Intelligence Algorithms
TABLE 8.1 (Continued)
Neurological Disorders and Their Symptoms, Pathophysiology, and
Common Risk Factors
Neurological Pathophysiological
Disorders Symptoms Mechanism Risk Factors
Neuroinfections Fever, pain, swelling, Occur if microorganisms Certain age groups,
redness, impaired invade the nervous poor immune system,
function. In the case of system. Encephalitis, certain geographical
some viral infections, meningitis, HIV-AIDS, locations, autoimmune
drowsiness, confusion, fungal infections, disease, smoking,
and convulsions may parasitic infections, brain surgery.
occur. prion diseases, bacterial
infections such as Lyme
disease, tuberculosis,
syphilis, brain abscess.
Brain tumor Headaches, seizures Tumors can invade, Risk increases with
(ts), nausea and inltrate, or supplant age, genetics, and
vomiting, drowsiness, normal parenchymal exposure to radiation.
mental or behavioral tissue, disrupting
changes, such as normal function, and
memory problems. can cause increased
intracranial pressure.
Amiotrophic lateral Muscle twitches; muscle Degeneration of Genetics, exposure to
sclerosis cramps; tight and stiff pyramidal Betz cells in heavy metal,
muscles (spasticity); the motor cortex, pesticides, head
muscle weakness anterior horn cells of trauma, stroke,
affecting an arm, a leg, spinal cord, lower magnetic eld, and
or the neck. cranial motor nuclei of hypertension.
the brainstem.
Cerebral aneurysm Headaches, eye pain, Ballooning from wall of Genetics, advancing
vision change. the blood vessels in age, alcohol
the brain. If it expands consumption,
and the blood vessel atherosclerosis,
wall becomes too thin, cigarette smoking.
the aneurysm will
rupture and bleed.
self-medication. Several lipids have been shown to affect the BBB and facilitate drug
delivery into the brain after systemic circulation: oleic acid, triolein, alkylglycerols,
and conjugates of linoleic and myristic acid [10]. These examples suggest exploring
novel lipids for oral drug administration for neurodisorders.
8.2.2 INTRAVENOUS INJECTION
Intravenous administration is advantageous as it bypasses the GI tract and gives
highest bioavailability. However, large molecular size and hydrophilicity often limit
93 Targeted Drug Delivery for Neurological Disorders
BBB penetration. Strategies like use of viral vectors, nonviral vectors (nanoparticle,
exosomes, etc.), prodrug design, or conjugation with BBB-shuttle peptides improve
CNS uptake [1].
8.2.3 INTRATHECAL INJECTION
The intrathecal injection method has many important applications, such as treating
meningitis or spinal cord injuries, spinal anesthesia, pain management, and chemotherapy. This injection method bypasses the BBB and delivers a drug directly
into the CNS. The drug is injected into the cerebrospinal uid (CSF) via lumbar
puncture [11].
8.2.4 INTRANASAL DELIVERY
The drug is carried through the olfactory and trigeminal nerve pathways to the brain.
This route, due to shorter physical distance, offers rapid delivery of drug into the
brain. Also, the nose-to-brain lymphatic system has been proposed as a novel target
for neurological disorders [12].
8.2.5 INTRA-ARTERIAL INFUSION
This method identies the carotid or vertebral arteries supplying blood to the brain,
to which drug is directly infused. It is particularly benecial for acute stroke interventions. In recent decades, intra-arterial administration of anticancer drugs has
been considered a suitable alternative drug delivery route to intravenous and oral
administration [13].
8.3 IMPORTANCE OF TARGETED DRUG DELIVERY
FOR NEUROLOGICAL DISORDERS
Targeted drug delivery into the brain has gained attention of researchers worldwide in the treatment of neurological disorders, addressing the challenges of
BBB penetration, site-specic drug release, and minimizing systemic side effects
(Table 8.2). The BBB is an important immunological feature of the CNS, which
restricts most drugs from entering the brain [14]. Targeted delivery systems have
demonstrated signicant advantages over conventional therapies in neurological
disorders like Alzheimer’s disease and Parkinson’s disease by encapsulating antiinammatory agents or neuroprotective compounds within nanoparticles to mitigate neuro-inammation and oxidative stress [15]. A drug molecule must possess
the required physicochemical properties for efcient permeation across the BBB.
However, nding all these properties in drug molecules is a formidable task, and
indeed most drugs fall away from these properties [16]. Nonpermeability is often an
issue with macromolecular pharmaceuticals, including peptides, proteins, antibodies,
and oligonucleotides [17]. There have been prodigious efforts to enhance drug diffusion into the brain parenchyma, including chemical modication of drugs, chemically or osmotically opening of tight junctions, physical disruption of the BBB layer,
Соседние файлы в папке Библиотека им академика М.И. Перельмана